Stress Urinary Incontinence (SUI) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Stress urinary incontinence (SUI) is the sudden, involuntary loss of urine caused by heightened intraabdominal pressure, adversely affecting the patient’s quality of life. Activities such as laughing, sneezing, straining, coughing, or exercising can trigger SUI, leading patients to describe the experience as “leaking,” “dripping,” or “flooding.” Initial urinary complaints may include frequency, urgency, and dysuria.
The etiologies of stress urinary incontinence are diverse and include:
- Loss of support from pelvic floor musculature and connective tissue stemming from factors such as connective tissue disorders, chronic cough, obesity, pelvic floor trauma post-vaginal delivery, pregnancy, menopause, constipation, heavy lifting, and smoking.
- Neuromuscular damage resulting from prior pelvic surgeries.
In addition to SUI, three other types of incontinence merit consideration:
- Overflow incontinence, characterized by continuous urinary leakage due to incomplete bladder emptying
- Urge incontinence, involving involuntary urine loss associated with a compelling, difficult-to-defer urge to void
- Mixed incontinence, marked by involuntary urine loss with elements of both urge and stress
Managing stress urinary incontinence involves behavioral, pharmacological, and surgical approaches. Pharmacological options include:
- Oxybutynin, an anti-cholinergic that inhibits detrusor contractions by blocking muscarinic receptors in the bladder’s smooth muscle.
- Tricyclic anti-depressants exert alpha-adrenergic effects, aiding urethral contraction and closure.
- Topically applied estrogen to enhance urethral blood flow and the sensitivity of alpha-adrenergic receptors.
Stress UI tends to increase during pregnancy compared to pre-pregnancy, while urge UI remains relatively stable. In the initial three months postpartum, the prevalence of UI is 30%, with most women experiencing stress UI.
Thelansis’s “Stress Urinary Incontinence (SUI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stress Urinary Incontinence (SUI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Stress Urinary Incontinence (SUI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Stress Urinary Incontinence (SUI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
